Cargando…

S110: PHALLCON: A PHASE 3 STUDY COMPARING PONATINIB VERSUS IMATINIB IN NEWLY DIAGNOSED PH+ ALL

Detalles Bibliográficos
Autores principales:	Jabbour, Elias, Kantarjian, Hagop, Aldoss, Ibrahim, Montesinos, Pau, Leonard, Jessica, Gomez, David, Baer, Maria, Gambacorti-Passerini, Carlo, Mccloskey, James, Minami, Yosuke, Papayannidis, Cristina, Rocha, Vanderson, Rousselot, Philippe, Vachhani, Pankit, Wang, Eunice, Hennessy, Meliessa, Patel, Niti, Vorog, Alexander, Wang, Bingxia, Yao, Huilan, Yeh, Tammie, Maria Ribera, Josep
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Oral Sessions
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428451/ http://dx.doi.org/10.1097/01.HS9.0000967352.68516.d0

Ejemplares similares

PB1762: PONATINIB VERSUS IMATINIB WITH REDUCED-INTENSITY CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME–POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): PHALLCON STUDY
por: Jabbour, E., et al.
Publicado: (2022)

Ponatinib after failure of second‐generation tyrosine kinase inhibitor in resistant chronic‐phase chronic myeloid leukemia
por: Kantarjian, Hagop M., et al.
Publicado: (2022)

P364: A PHASE II STUDY OF LOW-INTENSITY CHEMOTHERAPY (MINI-HYPER-CVD) AND PONATINIB FOLLOWED BY BLINATUMOMAB AND PONATINIB IN PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA
por: Haddad, Fadi, et al.
Publicado: (2023)

Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies
por: Sonnichsen, Daryl, et al.
Publicado: (2013)

P662: POST HOC ANALYSIS OF PATIENT RESPONSES BY T315I MUTATION STATUS FROM THE 3-YEAR UPDATE OF THE OPTIC TRIAL: A DOSE-OPTIMIZATION STUDY OF 3 STARTING DOSES OF PONATINIB
por: Cortes, Jorge, et al.
Publicado: (2023)

Ponatinib, chemotherapy, and transplant in adults with Philadelphia chromosome–positive acute lymphoblastic leukemia
por: Ribera, Josep-Maria, et al.
Publicado: (2022)

Isolated Gastric Myeloid Sarcoma: A Case Report and Review of the Literature
por: Vachhani, Pankit, et al.
Publicado: (2014)

Spotlight on pembrolizumab in non-small cell lung cancer: the evidence to date
por: Vachhani, Pankit, et al.
Publicado: (2016)

Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review
por: Jabbour, Elias, et al.
Publicado: (2010)

How the COVID-19 Pandemic Reshaped the Management of Leukemia and Affected Patient Outcomes
por: Sharafeldin, Noha, et al.
Publicado: (2022)

S118: A CHEMOTHERAPY-FREE COMBINATION OF PONATINIB AND BLINATUMOMAB FOR PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA: SUBGROUP ANALYSIS FROM A PHASE II STUDY
por: Short, Nicholas, et al.
Publicado: (2023)

Development and targeted use of nilotinib in chronic myeloid leukemia
por: Fava, Carmen, et al.
Publicado: (2009)

Ponatinib enhances anticancer drug sensitivity in MRP7-overexpressing cells
por: SUN, YUE-LI, et al.
Publicado: (2014)

Ponatinib‐induced ichthyosiform eruption
por: Kluger, Nicolas, et al.
Publicado: (2021)

Long‐term patient‐reported outcomes from an open‐label safety and efficacy study of bosutinib in Philadelphia chromosome–positive chronic myeloid leukemia patients resistant or intolerant to prior therapy
por: Kantarjian, Hagop M., et al.
Publicado: (2017)

Remission of Severe, Relapsed, and Refractory TTP after Multiple Cycles of Bortezomib
por: Pandey, Manu R., et al.
Publicado: (2017)

Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome‐positive leukemias with the T315I mutation
por: Nicolini, Franck E., et al.
Publicado: (2017)

Suboptimal Responses in Chronic Myeloid Leukemia
por: Jabbour, Elias, et al.
Publicado: (2012)

Eruptive melanocytic nevi associated with ponatinib
por: Devred, Inès, et al.
Publicado: (2018)

Ponatinib-Induced Cerebrovascular Accident (CVA)
por: Azad, Farhan, et al.
Publicado: (2022)

Reengineering Ponatinib to Minimize Cardiovascular Toxicity
por: Hnatiuk, Anna P., et al.
Publicado: (2022)

Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions
por: Samra, Bachar, et al.
Publicado: (2020)

Long‐term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib
por: Cortes, Jorge E., et al.
Publicado: (2016)

Effects of Ketoconazole on the Pharmacokinetics of Ponatinib in Healthy Subjects
por: Narasimhan, Narayana I, et al.
Publicado: (2013)

Effects of food on the pharmacokinetics of ponatinib in healthy subjects
por: Narasimhan, NI, et al.
Publicado: (2013)

P670: EARLY CYTOGENETIC OR MOLECULAR LANDMARK RESPONSE TO PONATINIB TREATMENT PREDICTS OUTCOMES IN HEAVILY PRETREATED PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA IN PACE: 5-YEAR DATA
por: Müller, Martin C., et al.
Publicado: (2023)

All-trans-retinoic-acid and arsenic trioxide induced remission in promyelocytic blast crisis
por: Colvin, Teresa A., et al.
Publicado: (2018)

Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia
por: Gambacorti-Passerini, Carlo, et al.
Publicado: (2014)

P379: PONATINIB AND BLINATUMOMAB IN RELAPSED/REFRACTORY PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA OR CHRONIC MYELOID LEUKEMIA IN LYMPHOID BLAST PHASE: SUBGROUP ANALYSIS FROM A PHASE II TRIAL
por: Haddad, Fadi, et al.
Publicado: (2023)

Novel monoclonal antibody-based treatment strategies in adults with acute lymphoblastic leukemia
por: Guerra, Veronica A., et al.
Publicado: (2019)

Inotuzumab ozogamicin for the treatment of acute lymphoblastic leukemia
por: Savoy, J. Michael, et al.
Publicado: (2018)

Resistant mutations in CML and Ph(+)ALL – role of ponatinib
por: Miller, Geoffrey D, et al.
Publicado: (2014)

Ponatinib and other CML Tyrosine Kinase Inhibitors in Thrombosis
por: Zeng, Peng, et al.
Publicado: (2020)

Factors influencing long‐term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib
por: Brümmendorf, Tim H., et al.
Publicado: (2015)

Long‐term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors
por: Gambacorti‐Passerini, Carlo, et al.
Publicado: (2015)

Ponatinib vs. Imatinib as Frontline Treatment for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Matching Adjusted Indirect Comparison
por: Ribera, Josep-Maria, et al.
Publicado: (2023)

The BCR-ABL1 Inhibitors Imatinib and Ponatinib Decrease Plasma Cholesterol and Atherosclerosis, and Nilotinib and Ponatinib Activate Coagulation in a Translational Mouse Model
por: Pouwer, Marianne G., et al.
Publicado: (2018)

Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review
por: Cortes, Jorge E., et al.
Publicado: (2018)

A cellular screen identifies ponatinib and pazopanib as inhibitors of necroptosis
por: Fauster, A, et al.
Publicado: (2015)

RET fusions observed in lung and colorectal cancers are sensitive to ponatinib
por: Gozgit, Joseph M., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_i0nn8mgfcrks18mfmd1qq2qm16